The U.S Food and Drug Administration has approved a novel molecular drug that is capable of preventing fungal infections in post-surgical patients including those whose immune systems are weak.
Schering Corp.'s Noxafil (posaconazole) is now permitted for use, as a prevention of infections triggered by certain molds and yeast-like fungi called Aspergillus and Candida. This fungus easily penetrates the patients with a weak immune system including those whose count of white blood cells is low.
Noxafil has been declared safe and promising after successful clinical trials conducted on 1,844 subjects between ages 13 and 82. The FDA has however cautioned that the drug should be consumed after a full meal. Expected side effects of the drug could be nausea, vomiting, diarrhea, rash, and even a dip in blood potassium levels. Certain severe side effects observed in very rare cases could manifest as problems with the heart or liver functions.